AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15902529 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberoptic bronchoscopy
Number of subjects: 262
Study 15902529 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Gram stain, culture, and detection of pneumococcal antigen
Number of subjects: 262
Study 15902529 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing of urine for pneumococcal antigen
Number of subjects: 262
Study 12154113 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 48
Study 12154113 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 48
Study 12154113 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 48
Study 12154113 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute ascorbic acid infusion
Number of subjects: 48
Study 9926739 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin/clavulanate 3.1 g every 6 hours
Number of subjects: 137
Study 9926739 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilistatin 500 mg every 6 hours
Number of subjects: 137
Study 8780327 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 0
Study 8780327 — intervention group
Group type: COMPARATOR
Intervention: Electrophysiologic Study (EPS)
Number of subjects: 0
Study 8780327 — intervention group
Group type: COMPARATOR
Intervention: Holter monitoring
Number of subjects: 0
Study 8780327 — intervention group
Group type: COMPARATOR
Intervention: Sodium channel blocking drugs
Number of subjects: 0
Study 1937843 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet concentrates from AS-104
Number of subjects: 115
Study 1937843 — intervention group
Group type: COMPARATOR
Intervention: Platelet concentrates from CS-3000
Number of subjects: 115
Study 1937843 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet concentrates from AS-104 stored in teflon bags
Number of subjects: 115
Study 1937843 — intervention group
Group type: COMPARATOR
Intervention: Platelet concentrates from CS-3000 stored in polyolefine bags
Number of subjects: 115
Study 7082525 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous lumbar extradural analgesia
Number of subjects: 64
Study 7082525 — intervention group
Group type: COMPARATOR
Intervention: Control group (no extradural analgesia)
Number of subjects: 64
Study 7082525 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 64
Study 7082525 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of extradural block
Number of subjects: 64
Study 31471833 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance abuse (Tobacco, Alcohol, Psychotropic Drugs)
Number of subjects: 1000
Study 31471833 — intervention group
Group type: COMPARATOR
Intervention: Parental control and regulations
Number of subjects: 1000
Study 31867913 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 90
Study 31867913 — intervention group
Group type: EXPERIMENTAL
Intervention: Catgut embedding
Number of subjects: 90
Study 31867913 — intervention group
Group type: COMPARATOR
Intervention: Education group
Number of subjects: 90
Study 28641363 — intervention group
Group type: EXPERIMENTAL
Intervention: OXN PR (up to 160/80 mg daily)
Number of subjects: 243
Study 28641363 — intervention group
Group type: COMPARATOR
Intervention: OxyPR
Number of subjects: 243
Study 28641363 — intervention group
Group type: EXPERIMENTAL
Intervention: OXN PR
Number of subjects: 243
Study 28641363 — intervention group
Group type: EXPERIMENTAL
Intervention: OXN PR and OxyPR
Number of subjects: 243
Study 26071192 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 10
Study 26071192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 23660099 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium added enteral nutrition (P+EN)
Number of subjects: 70
Study 23660099 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition (PN)
Number of subjects: 70
Study 23660099 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (P+EN, EN, PN)
Number of subjects: 70
Study 22072411 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT)
Number of subjects: 86
Study 18164644 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy
Number of subjects: 191
Study 18164644 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor control exercise
Number of subjects: 191
Study 18164644 — intervention group
Group type: EXPERIMENTAL
Intervention: General exercise program
Number of subjects: 191
Study 18164644 — intervention group
Group type: COMPARATOR
Intervention: Pre-treatment stiffness
Number of subjects: 191
Study 17704850 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational swimming combined with asthma education (twice a week for 1 hour over 6 months)
Number of subjects: 65
Study 17704850 — intervention group
Group type: COMPARATOR
Intervention: Low doses of inhaled corticosteroids (ICS) and short-acting beta2 agonists (salbutamol as needed)
Number of subjects: 65
Study 17704850 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Group A and Group B at study end
Number of subjects: 65
Study 15078472 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir followed by interferon-alpha-2a
Number of subjects: 14
Study 15078472 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine followed by interferon-alpha-2a
Number of subjects: 14
Study 15078472 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (famciclovir or lamivudine + interferon-alpha-2a)
Number of subjects: 14
Study 15078472 — intervention group
Group type: EXPERIMENTAL
Intervention: G1896A mutation subgroup
Number of subjects: 14
Study 11204308 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitor (fosinopril) and a statin (pravastatin)
Number of subjects: 508
Study 11204308 — intervention group
Group type: COMPARATOR
Intervention: Diuretic and lipid‐lowering diet
Number of subjects: 508
Study 9741405 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose weekly methotrexate (MTX) therapy (7.5‐12.5 mg/week)
Number of subjects: 6
Study 9768798 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg during sevoflurane anesthesia
Number of subjects: 0
Study 9768798 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg during isoflurane anesthesia
Number of subjects: 0
Study 9768798 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg during propofol anesthesia
Number of subjects: 0
Study 9768798 — intervention group
Group type: COMPARATOR
Intervention: Comparison of sevoflurane with isoflurane and propofol anesthesia
Number of subjects: 0
Study 2173470 — intervention group
Group type: EXPERIMENTAL
Intervention: Epstein-Barr virus (EBV)-specific transfer factor (TF)
Number of subjects: 27
Study 2173470 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 655204 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental pair (1 EMR student and 1 nonretarded student)
Number of subjects: 304
Study 655204 — intervention group
Group type: COMPARATOR
Intervention: Control pair (2 nonretarded students)
Number of subjects: 304
Study 31397769 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehab‐EMF (exercise rehabilitation)
Number of subjects: 22
Study 31397769 — intervention group
Group type: COMPARATOR
Intervention: C‐EMF (control group)
Number of subjects: 22
Study 25521867 — intervention group
Group type: EXPERIMENTAL
Intervention: Water jets intervention in 9 schools
Number of subjects: 2899
Study 25521867 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 schools that did not receive water jets)
Number of subjects: 2899
Study 23370417 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (1.25 mg)
Number of subjects: 25
Study 23370417 — intervention group
Group type: COMPARATOR
Intervention: Natural history (control)
Number of subjects: 25
Study 20691631 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Therapy (MT)
Number of subjects: 90
Study 20691631 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Number of subjects: 90
Study 19499738 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirulina supplement (10 grams per day)
Number of subjects: 160
Study 19499738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 17532088 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine and vitamins A-E, biotin, selenium, zinc, manganese, copper, magnesium, folic acid, Coenzyme Q for 6 months
Number of subjects: 70
Study 17532088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 15213559 — intervention group
Group type: EXPERIMENTAL
Intervention: nelfinavir
Number of subjects: 38
Study 15213559 — intervention group
Group type: COMPARATOR
Intervention: nevirapine
Number of subjects: 38
Study 11246298 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (hemoglobin concentration of 70 g/L, maintained between 70 and 90 g/L)
Number of subjects: 357
Study 11246298 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion strategy (hemoglobin concentration of 100 g/L, maintained between 100 and 120 g/L)
Number of subjects: 357
Study 11246298 — intervention group
Group type: COMPARATOR
Intervention: Both groups (restrictive and liberal)
Number of subjects: 357
Study 9731088 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine
Number of subjects: 1072
Study 9731088 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release dexfenfluramine
Number of subjects: 1072
Study 9731088 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined dexfenfluramine groups
Number of subjects: 1072
Study 9731088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1072
Study 8048734 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 50
Study 8048734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 3349001 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (15 mmol magnesium‐aspartate‐hydrochloride per day)
Number of subjects: 568
Study 3349001 — intervention group
Group type: COMPARATOR
Intervention: Placebo (aspartic acid)
Number of subjects: 568
Study 31929202 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 12
Study 31929202 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphoric acid
Number of subjects: 12
Study 31929202 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamond bur
Number of subjects: 12
Study 31929202 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamond bur + phosphoric acid
Number of subjects: 12
Study 31929202 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser
Number of subjects: 12
Study 31929202 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser + phosphoric acid
Number of subjects: 12
Study 31096934 — intervention group
Group type: EXPERIMENTAL
Intervention: blended cognitive behaviour therapy (bCBT)
Number of subjects: 88
Study 31096934 — intervention group
Group type: COMPARATOR
Intervention: care as usual (CAU)
Number of subjects: 88
Study 28336568 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinergic enhancement with donepezil
Number of subjects: 0
Study 28336568 — intervention group
Group type: COMPARATOR
Intervention: Dopaminergic enhancement with bromocriptine
Number of subjects: 0
Study 28336568 — intervention group
Group type: COMPARATOR
Intervention: Noradrenergic enhancement with guanfacine
Number of subjects: 0
Study 25426659 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES-ER, Endeavor Resolute)
Number of subjects: 154
Study 25426659 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES, Xience V)
Number of subjects: 154
Study 23269536 — intervention group
Group type: EXPERIMENTAL
Intervention: Single nucleotide polymorphisms (SNPs) associated with PSA levels from the first stage of sample (N=1,999) confirmed in the second stage (N=1,496).
Number of subjects: 3495
Study 23269536 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variants identified in the study.
Number of subjects: 3495
Study 23269536 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized PSA cutoff values based on associated SNPs.
Number of subjects: 3495
Study 21881323 — intervention group
Group type: EXPERIMENTAL
Intervention: hANP infusion in CKD patients (Group C)
Number of subjects: 134
Study 21881323 — intervention group
Group type: COMPARATOR
Intervention: Placebo in CKD patients (Group A)
Number of subjects: 134
Study 21881323 — intervention group
Group type: EXPERIMENTAL
Intervention: hANP infusion in non-CKD patients (Group D)
Number of subjects: 134
Study 21881323 — intervention group
Group type: COMPARATOR
Intervention: Placebo in non-CKD patients (Group B)
Number of subjects: 134
Study 19826386 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost in study eye (1 eye)
Number of subjects: 105
Study 19826386 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost in control eye (fellow eye)
Number of subjects: 105
Study 16951539 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin use
Number of subjects: 263
Study 16951539 — intervention group
Group type: COMPARATOR
Intervention: Control (not using pravastatin)
Number of subjects: 263
Study 11173169 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly urine testing (n=16)
Number of subjects: 53
Study 11173169 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly urine testing (n=18)
Number of subjects: 53
Study 11173169 — intervention group
Group type: COMPARATOR
Intervention: Random Drawing control (n=19)
Number of subjects: 53
Study 9430866 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin 1000 mg administered during the last hour of CT haemodialysis
Number of subjects: 8
Study 9430866 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin 1000 mg administered after dialysis
Number of subjects: 8
Study 8238160 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (ampicillin or erythromycin)
Number of subjects: 117
Study 8238160 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 117
Study 2862924 — intervention group
Group type: EXPERIMENTAL
Intervention: Clorazepate (an anxiolytic)
Number of subjects: 20
Study 2862924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30765398 — intervention group
Group type: EXPERIMENTAL
Intervention: Early stimulation group
Number of subjects: 60
Study 30765398 — intervention group
Group type: COMPARATOR
Intervention: Late stimulation group (control group)
Number of subjects: 60
Study 28779478 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sugar milkshake
Number of subjects: 133
Study 28779478 — intervention group
Group type: COMPARATOR
Intervention: High-fat milkshake
Number of subjects: 133
Study 28779478 — intervention group
Group type: COMPARATOR
Intervention: Calorie-free, tasteless control solution
Number of subjects: 133
Study 27236889 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingfei Quyu Decoction (QQD), one dose per day for 8 weeks
Number of subjects: 120
Study 27236889 — intervention group
Group type: COMPARATOR
Intervention: Control group (no QQD)
Number of subjects: 120
Study 24799484 — intervention group
Group type: COMPARATOR
Intervention: CVI FU (225 mg/m2, 5 days per week)
Number of subjects: 1608
Study 24799484 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine (825 mg/m2, twice per day, 5 days per week)
Number of subjects: 1608
Study 24799484 — intervention group
Group type: EXPERIMENTAL
Intervention: CVI FU with oxaliplatin (50 mg/m2 once per week for 5 weeks)
Number of subjects: 1608
Study 24799484 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine with oxaliplatin (50 mg/m2 once per week for 5 weeks)
Number of subjects: 1608
Study 24799484 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin (50 mg/m2 once per week for 5 weeks)
Number of subjects: 1608
Study 22906130 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD6482 (1 μm)
Number of subjects: 0
Study 22906130 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD6482 (2.3 μm)
Number of subjects: 0
Study 22906130 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD6482 (27 μm)
Number of subjects: 0
Study 22906130 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD6482 (5.3 μm)
Number of subjects: 0
Study 22906130 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD6482
Number of subjects: 0
Study 20332506 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated advance care planning
Number of subjects: 309
Study 20332506 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 309
Study 17483955 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI per OS with 6% mannitol solution
Number of subjects: 40
Study 17483955 — intervention group
Group type: COMPARATOR
Intervention: MRE with nasojejunal intubation and polyethylenglycol solution
Number of subjects: 40
Study 15706336 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided design body jacket
Number of subjects: 30
Study 15706336 — intervention group
Group type: COMPARATOR
Intervention: Traditional body jacket
Number of subjects: 30
Study 12499885 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop group (STOP) - 10 mg prednisolone stopped after day 7 posttransplantation
Number of subjects: 62
Study 12499885 — intervention group
Group type: COMPARATOR
Intervention: Tapering group (TAP) - Gradually wean off steroids in 3 to 6 months
Number of subjects: 62
Study 9585276 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine continuous intravenous infusion after a loading dose of 0.05 mg/kg, aiming for a steady-state concentration of 20 ng/mL.
Number of subjects: 26
Study 9585276 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine continuous intravenous infusion after a loading dose of 0.05 mg/kg.
Number of subjects: 26
Study 7636320 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia (water temperature 39.5 degrees C) for 2 hours
Number of subjects: 8
Study 7636320 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin in hyperthermic conditions
Number of subjects: 8
Study 7636320 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin in thermoneutral conditions (34.5 degrees C)
Number of subjects: 8
Study 7636320 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin in both hyperthermic and control experiments
Number of subjects: 8
Study 7636320 — intervention group
Group type: COMPARATOR
Intervention: Control (thermoneutral water at 34.5 degrees C) for 2 hours
Number of subjects: 8
Study 2664258 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin (RU) 300 mg daily for 3 to 7 days
Number of subjects: 270
Study 2664258 — intervention group
Group type: COMPARATOR
Intervention: Josamycin (JM) 1200 mg daily for 3 to 7 days
Number of subjects: 270
Study 401529 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue valves (homografts)
Number of subjects: 99
Study 401529 — intervention group
Group type: COMPARATOR
Intervention: Starr‐Edwards prosthetic valves
Number of subjects: 99
Study 31679677 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 34
Study 31679677 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous surgery
Number of subjects: 34
Study 31679677 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgery
Number of subjects: 34
Study 26479144 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemia-tolerant mesenchymal stem cells (MSCs)
Number of subjects: 20
Study 26479144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 25585664 — intervention group
Group type: EXPERIMENTAL
Intervention: etravirine plus darunavir/ritonavir (DRV group)
Number of subjects: 1115
Study 25585664 — intervention group
Group type: COMPARATOR
Intervention: etravirine plus an alternative boosted protease inhibitor (other PI group)
Number of subjects: 1115
Study 23850111 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention program including physical exercise, recreational activities, and nutritional counseling for 12 weeks (three times weekly)
Number of subjects: 44
Study 23850111 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 44
Study 21831277 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly health education workshops alone (Group 1)
Number of subjects: 28
Study 21831277 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly health education workshops combined with family orientation through home visits (Group 2)
Number of subjects: 28
Study 19027962 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-Hz rTMS
Number of subjects: 22
Study 19027962 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Hz rTMS
Number of subjects: 22
Study 19027962 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 22
Study 17069496 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) for 10 sessions per day excluding weekends
Number of subjects: 39
Study 17069496 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser treatment
Number of subjects: 39
Study 15312405 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-released-gliclazide
Number of subjects: 159
Study 15312405 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide
Number of subjects: 159
Study 10930801 — intervention group
Group type: EXPERIMENTAL
Intervention: Video information cassette
Number of subjects: 220
Study 10930801 — intervention group
Group type: COMPARATOR
Intervention: Non-video group (control)
Number of subjects: 220
Study 9007680 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg (B)
Number of subjects: 16
Study 9007680 — intervention group
Group type: COMPARATOR
Intervention: Placebo (A)
Number of subjects: 16
Study 9007680 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial compliance (C)
Number of subjects: 16
Study 9007680 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose (D)
Number of subjects: 16
Study 8497632 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitized images
Number of subjects: 108
Study 8497632 — intervention group
Group type: COMPARATOR
Intervention: Conventional film images
Number of subjects: 108
Study 3433917 — intervention group
Group type: EXPERIMENTAL
Intervention: RA 27/3 rubella vaccine
Number of subjects: 631
Study 3433917 — intervention group
Group type: COMPARATOR
Intervention: Control group (not immunized)
Number of subjects: 631
Study 30920255 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 95